Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gazyva
Pharma
Roche's Gazyva succeeds in key lupus nephritis trial
Roche has shown results of a phase 3 trial which set up Gazyva for potential approval in what would be its most important indication—lupus nephritis.
Kevin Dunleavy
Feb 7, 2025 11:14am
Roche's Gazyva chases new kidney disease use with phase 3 win
Sep 26, 2024 11:30am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm
FDA probes TG Therapeutics' Ukoniq for potential death risks
Feb 7, 2022 9:53am
Roche lands approval to slash Gazyvaro infusion time in EU
Oct 19, 2021 7:10am
AbbVie, J&J eye new Imbruvica CLL use in fixed-duration combo
Jun 12, 2021 3:00am
